Guideline of guidelines: non‐muscle‐invasive bladder cancer

• Published in: BJU international Vol. 119; no. 3; pp. 371 - 380
• Main Authors: Woldu, Solomon L., Bagrodia, Aditya, Lotan, Yair
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2017
• Subjects: Bladder cancer; BladderCancer; blcsm; guidelines; Humans; management; Muscle, Smooth; Neoplasm Invasiveness; non‐muscle‐invasive bladder cancer; Practice Guidelines as Topic; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy; guidelines; blcsm; BladderCancer; management; non-muscle-invasive bladder cancer
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.13760

Non‐muscle‐invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk‐adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.